ARK Genomic Revolution ETF ARKG

The Motley Fool 18 oct

Cathie Wood's ARK Invest purchased $3.4 million worth of CRISPR Therapeutics stock on consecutive trading days (Oct. 9 and Oct. 12), bringing her total holdings to $379.1 million. The investment reflects confidence in CRISPR's approved therapy Casgevy and promising pipeline candidates CTX-310 and CTX611, despite the stock declining 25% over the past year. CRISPR reported strong Q2 revenue growth of 151% year-over-year and maintains $2.36 billion in cash.

The Motley Fool 31 ago

Cathie Wood's Ark Invest added to positions in Nvidia, Broadcom, and Intellia Therapeutics on Friday as these stocks declined. Nvidia exceeded earnings expectations with 106% revenue growth and raised guidance to 70% for fiscal 2028, now trading at 14x forward earnings. Broadcom is on track for accelerating growth with an upcoming earnings report. Intellia, a gene-editing biotech, has declined over 50% from recent highs but remains well-funded with analyst support.

The Motley Fool 22 jul

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

The Motley Fool 19 jul

Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.